Fé, vida e morte: representações imagéticas de uma América espanhola crente

The small photo essay below presents some photographs captured in the city of Lima in Peru in March 2020, what we didn’t know is that this would be one of the last months before the pandemic that would change our looks, feelings and behavior. With the intention of causing strangeness, the photographs present from everyday aspects of the local religiosity, to others that are very delicate and impactful to the external eye, such as the suicide hall in the largest local cemetery, or the tombs of witches, revered even after death in the same cemetery.O pequeno ensaio fotográfico a seguir, apresenta algumas fotografias capturadas na cidade de Lima no Peru em março de 2020, o que não sabíamos, é que este seria um dos últimos meses antes da pandemia que mudaria nossos olhares, sentimentos e comportamentos. Com a intenção de causar estranhamento, as fotografias apresentam desde aspectos cotidianos da religiosidade local, até outros muito delicados e impactantes ao olhar externo, como o corredor dos suicidas, no maior cemitério local, ou as tumbas de bruxas, reverenciadas mesmo depois de mortas no mesmo cemitério

Gastrectomia total: análise de 25 casos.

Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Departamento de Clínica Cirúrgica, Curso de Medicina, Florianópolis, 198

The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer.

Overexpression and/or hyperactivation of cyclin-dependent kinases (CDKs) are common features of most cancer types. CDKs have been shown to play important roles in tumor cell proliferation and growth by controlling cell cycle, transcription, and RNA splicing. CDK4/6 inhibitor palbociclib has been recently approved by the FDA for the treatment of breast cancer. CDK11 is a serine/threonine protein kinase in the CDK family and recent studies have shown that CDK11 also plays critical roles in cancer cell growth and proliferation. A variety of genetic and epigenetic events may cause universal overexpression of CDK11 in human cancers. Inhibition of CDK11 has been shown to lead to cancer cell death and apoptosis. Significant evidence has suggested that CDK11 may be a novel and promising therapeutic target for the treatment of cancers. This review will focus on the emerging roles of CDK11 in human cancers, and provide a proof-of-principle for continued efforts toward targeting CDK11 for effective cancer treatment

Coupled nonautonomous inclusion systems with spatially variable exponents

A family of nonautonomous coupled inclusions governed by p(x)-Laplacian operators with large diffusion is investigated. The existence of solutions and pullback attractors as well as the generation of a generalized process are established. It is shown that the asymptotic dynamics is determined by a two dimensional ordinary nonautonomous coupled inclusion when the exponents converge to constants provided the absorption coefficients are independent of the spatial variable. The pullback attractor and forward attracting set of this limiting system is investigated

Kemandirian Belajar Dalam Sistem Pembelajaran Jarak Jauh di Universitas Terbuka Daerah Sorong

Kegiatan Pengabdian Kepada Masyarakat ini, merupakan kerjasama Universitas Terbuka Daerah Sorong dengan Radio Republik Indonesia Kota Sorong. Kegiatan ini bertujuan untuk memberikan edukasi kepada masyarakat dan khususnya mahasiswa sehingga memahami konsep belajar mandiri untuk membentuk karakter yang mandiri dalam melaksanakan proses belajar pada sistem pembelajaran jarak jauh. Kegiatan ini dilakukan dengan metode sosialisai dalam bentuk live dialog interaktif. Hasil dari kegiatan ini adalah masyarakat mendapatkan edukasi terkait belajar mandiri dalam sistem pembelajaran jarak jauh, dan bagi mahasiswa mampu menerapkan belajar mandiri sehingga lebih siap dalam mengiktui proses pembelajran dengan semua sitem yang ada di Universitas Terbuka guna menunjang keigatan belajar mahasiswa

Transcriptional activation of CBFβ by CDK11p110 is necessary to promote osteosarcoma cell proliferation.

BACKGROUND:Aberrant expression of cyclin-dependent protein kinases (CDK) is a hallmark of cancer. CDK11 plays a crucial role in cancer cell growth and proliferation. However, the molecular mechanisms of CDK11 and CDK11 transcriptionally regulated genes are largely unknown. METHODS:In this study, we performed a global transcriptional analysis using gene array technology to investigate the transcriptional role of CDK11 in osteosarcoma. The promoter luciferase assay, chromatin immunoprecipitation assay, and Gel Shift assay were used to identify direct transcriptional targets of CDK11. Clinical relevance and function of core-binding factor subunit beta (CBFβ) were further accessed in osteosarcoma. RESULTS:We identified a transcriptional role of protein-DNA interaction for CDK11p110, but not CDK11p58, in the regulation of CBFβ expression in osteosarcoma cells. The CBFβ promoter luciferase assay, chromatin immunoprecipitation assay, and Gel Shift assay confirmed that CBFβ is a direct transcriptional target of CDK11. High expression of CBFβ is associated with poor outcome in osteosarcoma patients. Expression of CBFβ contributes to the proliferation and metastatic behavior of osteosarcoma cells. CONCLUSIONS:These data establish CBFβ as a mediator of CDK11p110 dependent oncogenesis and suggest that targeting the CDK11- CBFβ pathway may be a promising therapeutic strategy for osteosarcoma treatment

Systems of p-Laplacian differential inclusions with large diffusion

AbstractIn this paper we consider coupled systems of p-Laplacian differential inclusions and we prove, under suitable conditions, that a homogenization process occurs when diffusion parameters become arbitrarily large. In fact we obtain that the attractors are continuous at infinity on L2(Ω)×L2(Ω) topology, with respect to the diffusion coefficients, and the limit set is the attractor of an ordinary differential problem

Rhabdomyosarcoma: Advances in Molecular and Cellular Biology.

Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in childhood and adolescence. The two major histological subtypes of RMS are alveolar RMS, driven by the fusion protein PAX3-FKHR or PAX7-FKHR, and embryonic RMS, which is usually genetically heterogeneous. The prognosis of RMS has improved in the past several decades due to multidisciplinary care. However, in recent years, the treatment of patients with metastatic or refractory RMS has reached a plateau. Thus, to improve the survival rate of RMS patients and their overall well-being, further understanding of the molecular and cellular biology of RMS and identification of novel therapeutic targets are imperative. In this review, we describe the most recent discoveries in the molecular and cellular biology of RMS, including alterations in oncogenic pathways, miRNA (miR), in vivo models, stem cells, and important signal transduction cascades implicated in the development and progression of RMS. Furthermore, we discuss novel potential targeted therapies that may improve the current treatment of RMS

Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro.

Synovial sarcoma is an aggressive soft tissue sarcoma genetically defined by the fusion oncogene SS18-SSX. It is hypothesized that either SS18-SSX disrupts SWI/SNF complex inhibition of the polycomb complex 2 (PRC2) methyltransferase Enhancer of Zeste Homologue 2 (EZH2), or that SS18-SSX is able to directly recruit PRC2 to aberrantly silence target genes. This is of potential therapeutic value as several EZH2 small molecule inhibitors are entering early phase clinical trials. In this study, we first confirmed EZH2 expression in the 76% of human synovial sarcoma samples. We subsequently investigated EZH2 as a therapeutic target in synovial sarcoma in vitro. Knockdown of EZH2 by shRNA or siRNA resulted in inhibition of cell growth and migration across a series of synovial sarcoma cell lines. The EZH2 selective small-molecule inhibitor EPZ005687 similarly suppressed cell proliferation and migration. These data support the hypothesis that targeting EZH2 may be a promising therapeutic strategy in the treatment of synovial sarcoma; clinical trials are initiating enrollment currently